KEGG   DRUG: Naxitamab
Entry
D11416                      Drug                                   

Name
Naxitamab (USAN);
Naxitamab-gqgk;
Danyelza (TN)
Product
Formula
C6414H9910N1718O1996S44
Exact mass
144345.4479
Mol weight
144434.4882
Sequence
(Heavy chain)
QVQLVESGPG VVQPGRSLRI SCAVSGFSVT NYGVHWVRQP PGKGLEWLGV IWAGGITNYN
SAFMSRLTIS KDNSKNTVYL QMNSLRAEDT AMYYCASRGG HYGYALDYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
EIVMTQTPAT LSVSAGERVT ITCKASQSVS NDVTWYQQKP GQAPRLLIYS ASNRYSGVPA
RFSGSGYGTE FTFTISSVQS EDFAVYFCQQ DYSSFGQGTK LEIKRTVAAP SVFIFPPSDE
QLKSGTASVV CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK
ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C
(Disulfide bridge: H22-H95, H146-H202, H222-L211, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'211, H'263-H'323, H'369-H'427, L23-L88, L131-L191, L'23-L'88, L'131-L'191)
  Type
Peptide
Remark
Product: D11416<US>
Efficacy
Antineoplastic, Anti-GD2 antibody
  Disease
Neuroblastoma [DS:H00043]
Comment
Monoclonal antibody
Target
GD2 [GL:G00114]
Brite
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11416
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11416
Other DBs
CAS: 1879925-92-4
PubChem: 384585393
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system